Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

63%

5 trials in Phase 3/4

Results Transparency

100%

7 of 7 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 3

4(66.7%)

Phase 4

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 3(4)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02088073Phase 3Completed

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

Role: lead

NCT01737697Phase 3Completed

Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

Role: lead

NCT02107092Phase 3Completed

Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.

Role: lead

NCT01493024Phase 2Completed

Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia

Role: lead

NCT02163499Phase 3Completed

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

Role: lead

NCT02609841Completed

POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study

Role: lead

NCT02607085Completed

REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study

Role: lead

NCT01866709Phase 4Terminated

Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia

Role: lead

All 8 trials loaded